Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD200 in Pediatric Subjects With ADHD
NCT02255513Phase 3Completed
- Sponsor
- Ironshore Pharmaceuticals
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of HLD200 in attention deficit hyperactivity disorder (ADHD), sponsored by Ironshore Pharmaceuticals. Started May 2014; status: completed.
02
Drugs
HLD200
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02255513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255513.